EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways

Obsie T Baissa, Tomer Ben-Shushan, Ora Paltiel

Cancer Causes & Control · 2025-03 · 36 (3) · 199-230

DOI: 10.1007/s10552-024-01922-z ↗

Kurz gefasst

Scoping Review in der Zeitschrift Cancer Causes & Control, online erschienen am 17.10.2024. Verfasst von Obsie T Baissa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Braun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, …. Hauptthemen laut MEDLINE: Lymphoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Improving cancer outcomes in Sub-Saharan Africa (SSA) requires effective implementation of evidence-based strategies. This scoping review maps the evidence on lymphoma epidemiology, treatment challenges, and patient pathways in SSA from 2011 to 2022.

Methods

A comprehensive three-step search was conducted without language restrictions.

Results

Eighty-four publications were included, 83% published after 2017. Southern and Eastern Africa led in output. Most studies were chart reviews (47.6%) and cohort studies (25%). NHL accounted for over 80% of cases, with an age-standardized rate (ASR) reaching 10.9/100,000, while HL had an ASR of 0.4–2.3/100,000. Compared to studies in Europe and US, SSA studies reported lower incidence rates, higher HIV comorbidity, and younger median ages. Diagnosis is often delayed, incomplete and lacks sub-classification with HIV and tuberculosis further complicating care. One-year survival rates are around 50% for NHL and over 75% for HL. Treatment is well-tolerated with an acceptable treatment-related mortality rate. However, outcomes are affected by diagnostic delays, late presentations, and treatment abandonment. Non-clinical aspects of care such as financial constraints negatively impact patient pathways.

Conclusion

Addressing diagnostic delays, misdiagnosis, and treatment abandonment is crucial. Strengthening care access, diagnostics, and integrating innovative strategies including a multidisciplinary approach and re-designing efficient clinical diagnostic pathways are vital.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaHumansAfrica South of the SaharaIncidence

Stichwörter der Autor:innen

EpidemiologyHLLymphomaNHLPatient pathwaysScoping reviewSub-Saharan Africa

Autor:innen und Institutionen

  • Braun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Obsie.baissa@mail.huji.ac.il.
  • The Berman Medical Library, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Braun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Förderung

  • Hebrew University of Jerusalem

Zitieren

APA

Baissa, O. T., Ben-Shushan, T., & Paltiel, O. (2025). Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways. Cancer Causes & Control, 36(3), 199-230. https://doi.org/10.1007/s10552-024-01922-z

Vancouver

Baissa OT, Ben-Shushan T, Paltiel O. Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways. Cancer Causes & Control. 2025;36(3):199-230. doi:10.1007/s10552-024-01922-z

BibTeX
@article{Baissa2025,
  author = {Baissa, Obsie T and Ben-Shushan, Tomer and Paltiel, Ora},
  title = {Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways},
  journal = {Cancer Causes & Control},
  year = {2025},
  volume = {36},
  number = {3},
  pages = {199--230},
  doi = {10.1007/s10552-024-01922-z}
}
Kostenlos starten →